Primer on Medical Genomics Part XII: Pharmacogenomics - General Principles with Cancer as a Model

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of "standard" doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.

Original languageEnglish (US)
Pages (from-to)376-384
Number of pages9
JournalMayo Clinic Proceedings
Volume79
Issue number3
StatePublished - 2004

Fingerprint

Pharmacogenetics
Genomics
Pharmaceutical Preparations
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Human Genome Project
Poisons
Clinical Medicine
Therapeutics
Research Personnel
Physicians
Enzymes
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primer on Medical Genomics Part XII : Pharmacogenomics - General Principles with Cancer as a Model. / Goetz, Matthew Philip; Ames, Matthew M.; Weinshilboum, Richard M.

In: Mayo Clinic Proceedings, Vol. 79, No. 3, 2004, p. 376-384.

Research output: Contribution to journalArticle

@article{dbc65488b6f84ab08d1fdae27e472417,
title = "Primer on Medical Genomics Part XII: Pharmacogenomics - General Principles with Cancer as a Model",
abstract = "The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of {"}standard{"} doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.",
author = "Goetz, {Matthew Philip} and Ames, {Matthew M.} and Weinshilboum, {Richard M}",
year = "2004",
language = "English (US)",
volume = "79",
pages = "376--384",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Primer on Medical Genomics Part XII

T2 - Pharmacogenomics - General Principles with Cancer as a Model

AU - Goetz, Matthew Philip

AU - Ames, Matthew M.

AU - Weinshilboum, Richard M

PY - 2004

Y1 - 2004

N2 - The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of "standard" doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.

AB - The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of "standard" doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=1442355642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442355642&partnerID=8YFLogxK

M3 - Article

C2 - 15008610

AN - SCOPUS:1442355642

VL - 79

SP - 376

EP - 384

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -